Navigation Links
In Pain Market, Huge Unmet Needs, Tough Regulatory Environment Challenge Pharmaceutical Companies, According to MedPredict
Date:6/23/2008

SCOTTSDALE, Ariz., June 23 /PRNewswire/ -- MedPredict has published a new report designed to provide critical strategic insight for pharma and biotech companies hoping to identify the next blockbuster drug for pain management. The report, entitled "Thought Leader Insight & Analysis: Pain/Analgesics," is based on in-depth interviews conducted with a panel of specialists in anesthesiology, psychiatry, rheumatology, gastroenterology and primary care.

The diagnosis and treatment of nociceptive, neuropathic and somatic pain varies considerably depending on the physician specialty. MedPredict's panelists in each specialty outline their therapeutic goals and unmet needs in treating pain associated with cancer, fibromyalgia, trauma, rheumatoid and osteoarthritis, back injury, neuropathy, depression, migraine and Crohn's disease.

"Pain is subjective," said Dr. Jeffrey Berk, MedPredict's president. "If you think that you hurt, you hurt. This subjectivity makes the diagnosis and treatment of pain exceedingly difficult, and it presents enormous challenges for researchers trying to demonstrate analgesic efficacy versus placebo." One path to success will be to narrowly define the population being studied, as Lilly has done with duloxatine in diabetic neuropathy, according to Dr. Berk.

MedPredict's panelists predict successes and failures in a number of therapeutic targets, including mu receptor agonists/opioids, serotonergic/noradrenergics, sodium and calcium channel blockers, NMDA/glutamate, Alpha-2 agonist, (mGlu2/3), acetylcholine, AMPA, cannabinoid, NF Kappa b, TRPV1/vanilloids, stimulants, NSAIDs, hyaluronic acid, anti-IL-10 and anti-IL-1. They evaluate the development pipeline based on the medical potential, mechanism of action, reimbursement and regulatory environment and relevance of Schedule II status.

Companies/Partnerships discussed in this report include Allergan, Allergan/Acadia, Alpharma, Alpharma/Institut Biochimique, Amgen, Amgen
'/>"/>

SOURCE MedPredict
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Having Penetrated Israels Domestic Telephony Market, 012 Smile.Communications Prepares for Its Next Goal: Entering Israels Cellular Market
2. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
3. Unmet Needs Provide Challenges and Opportunities for Rheumatoid Arthritis Drug Developers According to MedPredict Report
4. Biotech Avoids Fall Out From Tough Quarter for Capital Markets
5. Bringing a New Rhythm to Cardiology Workflow: Siemens Demonstrates Answers to Cardiologys Toughest Questions
6. pH Balanced RepHresh Vaginal Gel(R) now Available to Women in Canada Attacking Tough, Embarrassing Feminine Issues
7. Biotech Drops Amid Tough Markets in February
8. ATS Medical Announces Canadian Regulatory Approval of the ATS Open Pivot AP360 Mechanical Heart Valve
9. Neuftec Responds to a Fundamental Inaccuracy in Oxonica PLCs Regulatory Announcement
10. PAREXEL Product Development and Regulatory Experts to Attend the 2008 BIO International Convention
11. European Regulatory Agency Supports OPAXIO(TM) Brand Name for Cell Therapeutics Lung Cancer Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , Aug. 28, 2014  Armetheon, Inc. ( ... novel mid- to late-stage cardiovascular drug candidates, today ... its first round of financing. The Series A ... Hercules Bioventures with participation from investors that included ... executive, Dr. Larry Hsu , the founder ...
(Date:8/28/2014)... USA (PRWEB) August 27, 2014 Scientists, ... month for SPIE Laser Damage 2014 symposium. ... materials for high-power lasers will run 14-17 September. The ... for optics and photonics . , The premier conference ... understanding laser damage to optical materials will engage researchers ...
(Date:8/28/2014)... Earlier this month, a report ... with the U.S. Air Force on the performance of ... that this type of fuel made from mustard seeds, ... important to America’s Eco friendly future. In fact, every ... to become independent of foreign oil over the next ...
(Date:8/28/2014)... 28, 2014 Supplementing their complete ... promotion for Eppendorf Safe Lock Centrifuge Tubes ... the highest quality tubes at an affordable price. ... customers doing chemical, medical, pharmaceutical, and life science ... not regularly able to afford Eppendorf products. , ...
Breaking Biology Technology:Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 3
... N.J., July 21 BioNeutral Group, Inc. ("BioNeutral") (OTC ... Science Company announced today that at ATS Labs using ... Antimicrobial passed the difficult Quantitative Disk Carrier test ... difficile (C.diff) present in this test ...
... , , PALO ALTO, Calif., July 21, ... third quarter of its fiscal year 2009 after 1:00 p.m. Pacific Time ... of its investor conference call to review those quarterly results is scheduled ... , That live webcast can be accessed from Varian, ...
... , , KENILWORTH, N.J., July 21 ... for the 2009 second quarter. , , ... given us the strength to again power through tough challenges - delivering ... Fred Hassan, chairman and CEO. , , ...
Cached Biology Technology:BioNeutral's Ygiene(TM) Hospital Grade Achieves a 100% Total Kill (Pass) Against the Life Threatening Clostridium Difficile (C.diff) Spores in Independent EPA Required Protocol Testing. 2BioNeutral's Ygiene(TM) Hospital Grade Achieves a 100% Total Kill (Pass) Against the Life Threatening Clostridium Difficile (C.diff) Spores in Independent EPA Required Protocol Testing. 3Schering-Plough Reports Financial Results for 2009 Second Quarter 2Schering-Plough Reports Financial Results for 2009 Second Quarter 3Schering-Plough Reports Financial Results for 2009 Second Quarter 4Schering-Plough Reports Financial Results for 2009 Second Quarter 5Schering-Plough Reports Financial Results for 2009 Second Quarter 6Schering-Plough Reports Financial Results for 2009 Second Quarter 7Schering-Plough Reports Financial Results for 2009 Second Quarter 8Schering-Plough Reports Financial Results for 2009 Second Quarter 9Schering-Plough Reports Financial Results for 2009 Second Quarter 10Schering-Plough Reports Financial Results for 2009 Second Quarter 11Schering-Plough Reports Financial Results for 2009 Second Quarter 12Schering-Plough Reports Financial Results for 2009 Second Quarter 13Schering-Plough Reports Financial Results for 2009 Second Quarter 14Schering-Plough Reports Financial Results for 2009 Second Quarter 15Schering-Plough Reports Financial Results for 2009 Second Quarter 16Schering-Plough Reports Financial Results for 2009 Second Quarter 17Schering-Plough Reports Financial Results for 2009 Second Quarter 18Schering-Plough Reports Financial Results for 2009 Second Quarter 19Schering-Plough Reports Financial Results for 2009 Second Quarter 20Schering-Plough Reports Financial Results for 2009 Second Quarter 21Schering-Plough Reports Financial Results for 2009 Second Quarter 22Schering-Plough Reports Financial Results for 2009 Second Quarter 23Schering-Plough Reports Financial Results for 2009 Second Quarter 24Schering-Plough Reports Financial Results for 2009 Second Quarter 25Schering-Plough Reports Financial Results for 2009 Second Quarter 26Schering-Plough Reports Financial Results for 2009 Second Quarter 27
(Date:8/27/2014)... NY (June, 2014) Outstanding basic research, a ... a dedication to patient care have earned the ... University Medical Center (CUMC) and NewYork-Presbyterian Hospital an ... the National Cancer Institute (NCI). The grant renews ... NCI-designated Comprehensive Cancer Centers in New York City ...
(Date:8/27/2014)... number of studies have shown that excessive ... of Parkinson,s disease. Previous studies from Chunyan ... in China have shown that baicalin prevented ... divalent metal transporter 1 expression, and increased ... of rotenone-induced Parkinson,s disease rats. However, the ...
(Date:8/27/2014)... of seven hours ago the Happy Camp Complex of ... California, the July complex had consumed 35,530 as of ... fires on the Happy Camp Ranger District of the ... area on August 11, 2014. All but three of ... is a list of contained fires and their size ...
Breaking Biology News(10 mins):Herbert Irving Comprehensive Cancer Center awarded $18 million grant 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 3Herbert Irving Comprehensive Cancer Center awarded $18 million grant 4Happy Camp and July Fire Complexes in California 2
... your body is telling you that your pace feels a little ... A new study, published online March 18 in the ... human running varies with speed and that each individual has an ... distance with the least effort. The result debunks the ...
... millions of people with diseases that starve eye tissue ... procedure being developed by researchers at Oak Ridge National ... of Tennessee. The technique uses a new class ... tissue being deprived of oxygen because of restricted blood ...
... of the benefits of cooling strategies to protect the ... to a wealth of cutting edge research, prime examples ... of Journal of Neurotrauma , a peer-reviewed journal ... The issue will be available free online at ...
Cached Biology News:Optimum running speed is stride toward understanding human body form 2ORNL, Southern Cal set sights on preventing blindness 2Therapeutic hypothermia is promising strategy to minimize tissue damage 2
... 25-Hydroxy Vitamin D kit is an ... of 25-hydroxyvitamin D (25-OH D) and ... or plasma. Our patented DIRECT assay ... precipitation and centrifugation and therefore facilitates ...
... The IDS Corticosterone kit is a competitive ... corticosterone in mouse or rat serum or ... sole, corticosteroid in rats and mice, and ... birds and reptiles. Most mammals produce both ...
Mouse monoclonal [BC-4] to Aggrecan xxPEN ( Abpromise for all tested applications). entrezGeneID: 176 SwissProtID: P16112...
Mouse monoclonal [1.F.1] to Yersinia pestis F1 antigen ( Abpromise for all tested applications). Antigen: Purified F1 antigen of Y. pestis vaccine strain EB....
Biology Products: